Skip to main content
Amit Etkin, MD, Psychiatry, Stanford, CA

Amit Etkin MD


Associate Professor, Psychiatry & Behavioral Science, Stanford University Faculty, Stanford Neurosciences Institute, Stanford University Investigator, MIRECC, Palo Alto VA

Join to view full profile
  • 401 Quarry RdStanford, CA 94304

  • Phone+1 650-723-6661

Dr. Etkin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Psychiatry, 2006 - 2010
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2006

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2007 - 2027
  • Psychiatry
    American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans  
    Jerome A Yesavage, Michael Thase, Steven D Forman, Amit Etkin, Mark S George, JAMA

Authored Content

  • Decoding MoodOctober 2018
  • Decoding MoodOctober 2018
  • S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018

Press Mentions

  • Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
    Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in SchizophreniaSeptember 9th, 2025
  • Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in the Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
    Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in the Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant DepressionJune 30th, 2025
  • Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
    Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203June 26th, 2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: